Femtosecond laser platform receives FDA approval for arcuate incision procedure

July 18, 2014

The VICTUS femtosecond laser platform from Bausch + Lomb Technolas has received FDA 510(k) clearance for creating arcuate cuts/incisions in the cornea in patients undergoing cataract surgery or other ophthalmic treatments that require those cuts.

BioOptics World Editors

The VICTUS femtosecond laser platform from Bausch + Lomb Technolas (Aliso Viejo, CA/Munich, Germany) has received FDA 510(k) clearance for creating arcuate cuts/incisions in the cornea in patients undergoing cataract surgery or other ophthalmic treatments that require those cuts.

Related: Laser cataract surgery: Clearly advanced

The company has been installing VICTUS systems in leading surgery centers globally since it received the CE mark in Europe in November 2011 and FDA clearance in July 2012. Today, the platform is approved for the creation of a corneal flap in patients undergoing LASIK surgery and anterior capsulotomy during cataract surgery, as well as penetrating arcuate incisions in the U.S. In Europe, the platform is approved for the aforementioned procedures as well as INTRACOR and lens fragmentation.

-----

Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)